



ASH Home [Blood App](#) [My Folders](#) [Alerts](#) [RSS](#)

[Sign In](#)



Leading the way in experimental and clinical research in hematology

search

[Advanced Search](#)

[Home](#) | [About Blood](#) | [Authors](#) | [Submit to Blood](#) | [Subscriptions](#) | [Classifieds](#)

[f](#) [t](#) [in](#)

[Current Issue](#)

[First Edition](#)

[Collections](#)

[All Issues](#)

[Abstracts](#)

[Video Library](#)

Home / December 6, 2014; Blood: 124 (21)

**i** No markup for post-processing

## Long-Term Safety Follow-up of a Randomized Trial of Darbepoetin Alpha and Intravenous Iron Following Autologous Hematopoietic Cell Transplantation

Aur lie Jaspers, MD\*,<sup>1</sup>, Frederic Baron, MD PhD<sup>2,3</sup>, Johan Maertens, MD PhD\*,<sup>4</sup>, Bernard J. M. De Prijck, MD\*,<sup>1</sup>, Henri (Rik) Schots, MDPH<sup>5</sup>, Christophe Bonnet, MD PhD\*,<sup>1,2</sup>, Kaoutar Hafraoui, MD\*,<sup>1</sup>, Evelyne Willems, MD PhD\*,<sup>1</sup>, Sophie Servais, MD PhD\*,<sup>3</sup>, Georges Fillet, MD PhD<sup>1,2</sup>, and Yves Beguin, MD PhD<sup>3,2</sup>

+ [Author Affiliations](#)

**Article**

[Info & Metrics](#)

[E-Letters](#)

[PDF](#)

December 06, 2014 [Table of Contents](#)

[← Previous](#)

### Abstract

We recently reported the efficacy of darbepoetin alpha (DA)(Aranesp<sup>®</sup>) and intravenous (IV) iron (Venofer<sup>®</sup>) on erythroid reconstitution following autologous hematopoietic cell transplantation (auto-HCT). Although short-term disease progression, infections or other safety events were not influenced by DA or IV iron, a longer follow-up was required as some meta-analyses suggest increased mortality in patients with cancer receiving erythropoiesis-stimulating agents (ESA), particularly when no concomitant chemotherapy is administered. Besides, some in vitro and animal studies raised the possible role of iron in tumor growth. Therefore, we analyzed long-term outcome to verify the safety of DA and IV iron.

We included 127 patients with myeloma (n=76), Hodgkin's lymphoma (n=8), aggressive (n=26) or indolent (n=12) non-Hodgkin's lymphoma and other diagnoses (n=5). Groups were well balanced for age, disease, disease stage and disease status at time of transplantation. They were randomized between no erythropoietic therapy (n=25), DA from day 28 post-auto-HCT (n=52) or DA + IV iron on days 28, 42 and 56 (n=50). We collected data about infections and other complications, disease status and overall survival (OS) from auto-HCT (between March 2004 and January 2008) up to January 2014. Patients given a second transplant were censored at that time.

During long-term follow-up (mean: 3.4 years), the incidence of infection remained comparable in the 3 groups. Specifically, 3 patients in the control group (12%), 8 in the DA group (15%) and 6 in the DA+iron group (12%) experienced at least one infection. The number of infections per patient

**Volume:** 124

**Issue:** 21

**Pages:** 3948 - 3948

**DOI:** <http://dx.doi.org/>

[Email](#)

[Save to My Folders](#)

[Citation Alert](#)

[Request Permissions](#)

[Correction Alert](#)

[Share](#)

[Citation Tools](#)

**Article**

**Info & Metrics**

**E-Letters**

**Related Articles**

No related articles found.

between day 126 (end of the study) and the last follow-up was  $0.2 \pm 0.7$ ,  $0.2 \pm 0.4$  and  $0.1 \pm 0.3$  in control, DA and DA+iron groups, respectively (NS).

During follow-up, 4/25 (16%) patients in control group, 13/52 (25%) in DA group and 6/50 (12%) in the DA+iron group experienced at least one complications (NS). While 3 patients (2 in the control group and 1 in the DA+iron group) presented a thrombosis on study, no other thrombo-embolic event occurred during follow-up. Two patients (1 in control group and 1 in DA group) developed a benign tumor, whereas 4 patients (3 in DA group and 1 in DA+iron group) presented a secondary malignancy (NS). Other complications were: hypertension (n=2, 1 in control and 1 in DA groups), ischemic cardiomyopathy (3 in DA group) with 1 myocardial infarction, 4 arrhythmias (1 in control and 3 in DA groups) with pacemaker requirement in 2 (1 in control and 1 in DA groups), peripheral arteriopathy (1 in DA group), diabetes (n=3, 2 in DA and 1 in DA+iron groups), radiopneumonitis (1 in control group), vasculitis (1 in DA group), nephritis (1 in DA and 1 in DA+iron groups), thyroiditis (1 in DA group), spondylarthritis (1 in DA+iron group), jaw osteonecrosis in myeloma patients treated with zoledronic acid (1 in DA and 1 in DA+iron groups), hip osteonecrosis (1 in DA+iron group), peripheral neuropathy (1 in DA and 1 in DA+iron groups), sudden transient deafness (1 in DA group) and sarcoidosis (1 in DA+iron group).

We did not observe any difference in survival. Indeed, 1-year OS were 100%, 88% and 100% and 5-year OS were 86%, 78% and 91% in the control, DA and DA+iron groups, respectively (p=0.43). Progression-free survival (PFS) were also similar in the 3 groups: 1-year and 5-year PFS were 85% and 71% in the control group, compared to 86% and 57% in the DA group and 94% and 78% in the DA+iron group (p=0.30).

In conclusion, DA and IV iron therapy following auto-HCT did not affect safety, disease outcome or survival in long-term analyses.

**Disclosures Beguin:** Amgen: Consultancy, Speakers Bureau; Vifor: Consultancy, Speakers Bureau.

- \* Asterisk with author names denotes non-ASH members.

© 2014 by The American Society of Hematology

[^ Back to top](#)

Articles by [Jaspers, A.](#)

Articles by [Beguin, Y.](#)

Articles by [Jaspers, A.](#)

Articles by [Beguin, Y.](#)

Advertisement

**New and Improved!**

**ASH Clinical News.org**

- **EASIER, ROBUST NAVIGATION**
- **ON-SITE MEETING REPORTING**
- **EXCLUSIVE VIDEO INTERVIEWS**

Advertisement

**Now Available!**

Read the latest Issue of *ASH Clinical News*! Click to read more and sign up for our e-newsletter.



Leading the way in experimental and clinical research in hematology

**American Society of Hematology**  
2021 L Street NW, Suite 900, Washington, DC 20036  
Phone 202-776-0544 | Fax 202-776-0545

[Current Issue](#)

[First Edition](#)

[Topics](#)

[Collections](#)

[All Issues](#)

[Abstracts](#)

[Subscriptions](#)

[About Blood](#)

[Newsroom](#)

[Public Access](#)

[Permissions](#)

[Order Reprints](#)

[Submit to Blood](#)

[Alerts](#)

[RSS](#)

[Blood App](#)

[Contact Us](#)

[Feedback](#)

**Information for:**

[Authors](#)

[Subscribers](#)

[Institutions/Librarians](#)

[Advertisers](#)

[ASH Privacy Policy](#)

[ASH Home](#)

[Research](#)

[Education](#)

[Advocacy](#)

[Meetings](#)

[ASH Store](#)



Copyright © 2015 by American Society of Hematology